Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Can Pembrolizumab Improve dMMR Endometrial Cancer Outcomes?
TOPLINE: Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient (dMMR) tumors, according to a subgroup analysis of a phase 3 study. METHODOLOGY: About 25%-30% of…
English